Systematic ReviewResearchWorkflowPatient Education

Carotid patch material showed little difference in long-term stroke outcomes

The Cochrane database of systematic reviews (PubMed)Aug 24, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

An updated Cochrane review found synthetic and biological patches generally produced similar long-term stroke-related outcomes after carotid endarterectomy, while evidence for uncommon perioperative harms remained very uncertain.

What NurseJet pulled from the source

Fifteen randomized trials involving 4,971 participants were included, with 12 studies and 2,021 procedures contributing to the main synthetic-versus-biological comparison. Synthetic patches probably made little or no difference in long-term stroke or death, and may make little or no difference in several other long-term outcomes; perioperative stroke, arterial rupture, and pseudoaneurysm evidence was very uncertain.

Why this matters for nurses

Cardiac, vascular, and neuro nurses monitor patients after carotid surgery for neurologic change, perfusion concerns, bleeding, and wound complications. The review supports maintaining the full postoperative surveillance pathway regardless of patch material.

Bedside takeaway

Use the same vigilant neurologic, airway, wound, and perfusion surveillance after carotid endarterectomy regardless of patch material.

How This Applies in Practice

Use this when: Receiving or monitoring a patient after carotid endarterectomy with patch angioplasty.

On your shift

Confirm the procedure, patch material, ordered neurologic checks, blood-pressure targets, and vascular assessment schedule during handoff.
Assess neurologic status, neck swelling, airway symptoms, incision findings, and perfusion at the ordered intervals.
Escalate any new deficit, expanding swelling, bleeding, airway concern, or perfusion change through the postoperative pathway.

Keep in mind: The review does not establish superiority of one patch category or exclude rare harms. Follow the vascular team's plan, facility policy, and provider orders.

Key takeaways

The update included 15 randomized trials involving 4,971 participants.
Synthetic versus biological patches probably made little or no difference in long-term stroke or death.
Long-term ipsilateral stroke, any stroke, and restenosis outcomes also showed little or no clear difference, but certainty was low.
Evidence for perioperative ipsilateral stroke, arterial rupture, and long-term pseudoaneurysm was very uncertain.

Practice implications

Confirm the operative details during handoff, perform ordered neurologic and vascular assessments, inspect the neck and incision, and promptly escalate new deficit, swelling, bleeding, airway concern, or perfusion change. Do not use patch material alone to infer a lower-risk recovery.

Limitations & cautions

Many trials were small, events were uncommon, confidence intervals were wide, and some studies had design limitations. Certainty ranged from moderate for long-term stroke or death to very low for several perioperative and structural outcomes.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The Cochrane database of systematic reviews (PubMed)

The Cochrane database of systematic reviews (PubMed). Synthetic versus biological patches for carotid endarterectomy.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42635089/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Pediatric emergency care (PubMed)Sep 7, 2026Research Article

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

Peds EmergencyAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 100 children. Vomiting episodes and oral tolerance at 6 and 12 hours did not differ significantly, while median hospital stay was 2 days with pantoprazole and 1 day with placebo.

Key takeaways

The median participant age was 14 months, and 67% of participants were male.
Oral tolerance at 12 hours was 86% in both groups.
The longer stay associated with pantoprazole requires cautious interpretation because this was a single-center trial.

Why this matters on shift

The trial does not support empiric intravenous proton-pump inhibition for persistent vomiting in pediatric acute gastroenteritis after ondansetron.

Bedside takeaway

Clarify the indication for empiric acid suppression and keep hydration and oral-tolerance assessment central to care.

Nursing implications

Prioritize the ordered hydration and oral-tolerance plan, document ongoing emesis, and clarify the indication before administering empiric acid suppression.

Limitations & cautions

Abstract-only summary. This was a single-center study of 100 children in Tehran, and the abstract does not describe adverse events or explain why hospitalization was longer in the pantoprazole group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Pediatric emergency care (PubMed). Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

European heart journal (PubMed)Sep 6, 2026Research Article

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPatient EducationAI summary · original source linked below

Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).

Key takeaways

At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Why this matters on shift

The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.

Bedside takeaway

Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.

Nursing implications

Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of neurosurgical anesthesiology (PubMed)Sep 4, 2026Research Article

A five-center randomized trial found similar rescue-opioid use and moderate-to-severe PACU pain with dexmedetomidine-based opioid-sparing analgesia and fentanyl-based analgesia during elective craniotomy for brain tumors.

Emergency ICUAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 500 adults. Moderate-to-severe PACU pain occurred in 145 of 242 assessed participants in the fentanyl group and 138 of 233 in the dexmedetomidine group, with no significant difference.

Key takeaways

Intraoperative rescue fentanyl use did not differ significantly between groups.
Hypotension was more common with dexmedetomidine, while postoperative shivering was less common.
Other in-hospital outcomes were similar between the two regimens.

Why this matters on shift

An opioid-sparing label did not translate into better early pain control in this trial, and the differing hypotension and shivering profiles remain relevant during perioperative handoff and recovery monitoring.

Bedside takeaway

Monitor pain, hemodynamics, sedation, and shivering in relation to the analgesic regimen and local protocol.

Nursing implications

During PACU and postoperative handoff, monitor pain, hemodynamics, sedation, and shivering according to the administered regimen and local protocol.

Limitations & cautions

Abstract-only summary. The trial involved elective tumor craniotomy at five Indian centers, both groups also received locoregional analgesia, and the abstract does not provide longer-term outcome results in detail.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of neurosurgical anesthesiology (PubMed). Opioid-Sparing Versus Opioid-Based Analgesia for Craniotomy: A Multicenter Randomized Controlled Trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

IV pantoprazole did not improve vomiting or oral tolerance in pediatric gastroenteritis

Targeted vitamin D did not significantly reduce major cardiovascular events after MI

Dexmedetomidine did not improve early pain outcomes versus fentanyl for craniotomy